Your Messages Inbox
Your Article Summary
See Latest ArticlesAstraZeneca announces FDA acceptance of New Drug Application for VIMOVO
AstraZeneca, 09/01/09
AstraZeneca announced that the US Food and Drug Administration has accepted the New Drug Application submitted on June 2009 by its development partner, POZEN, Inc., for VIMOVO tablets. VIMOVO is a fixed–dose combination of enteric–coated naproxen, a pain–relieving non–steroidal anti–inflammatory drug and immediate release esomeprazole, a proton pump inhibitor, under investigation for the treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk of developing NSAID–associated gastric ulcers.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Article Search
Sponsor